This led to gene expression downregulation and suppression of the BCR-ABL tyrosine kinase signaling pathway to induce CML cell apoptosis and inhibit proliferationin vitro andin vivo, suggesting a potential application for CML gene therapy. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.